anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose. Patient who did not receive glargine in the hospital, discharge on previous OAD + linagliptin once daily, and consider starting glargine at 0.15 unit/kg/day.
In one aspect, block copolymers are described herein. A block copolymer described herein, in some embodiments, comprises a first block comprising a polymer or oligomer formed from the reaction product of (i) a polycarboxylic acid or a polycarboxylic acid equivalent, (ii) a polyol, and (iii) an amino acid; and a second block comprising a polymer or oligomer that differs from the polymer or oligomer of the first block. In some cases, the polycarboxylic acid or polycarboxylic acid equivalent comprises citric acid, a citrate, or an ester of citric acid. The polyol can comprise an a,?-n-alkane diol, poly(ethylene glycol), or poly(propylene glycol). In some embodiments, the amino acid forms a pendant group of the polymer or oligomer of the first block and/or forms a luminescent 6-membered ring with the polycarboxylic acid or polycarboxylic acid equivalent. The second block of a block copolymer described herein, in some embodiments, comprises a polylactone.
Compositions comprising RIP are advantageously formulated in compositions allowing sustained release and protection from degradation, and improved therapeutic efficacy. To that end, RIP compositions may be delivered to the skin or mucosal membranes as a salve or the like. Alternatively or additionally, RIP compositions may be administered in polymeric nanoparticle carriers, which may be biodegradable. Such formulations are compatible with oral administration. The nanoparticle may accommodate a composition comprising a RIP and at least one other antimicrobial agent, e.g., an antibiotic or an antimicrobial peptide. The nanoparticle further may comprise a coating or moiety, such as an antibody or fragment thereof, to assist in cell targeting.
Received standardized medical therapy in an intensive care unit (ICU), which included elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L. Hyperglycemia, hyperthermia and hypotension were avoided or corrected when present.
The invention discloses a plaster for treating gastropathy and the preparation method, relates to a medical preparation from plants. The invention is composed of an adhesive layer, a protective layer and a lining layer. The drugs of the adhesive layer contain Herba Taraxaci 40-60g, Radix Paeoniae Alba 5-15g, Radix Glycyrrhizae 3-10g, Flos Carthami 4-14g, Radix Cynanchi Paniculati 8-16g, Pericarpium Citri Reticulatae 4-14g and Rhizoma Bolbostematis 8-16g. The effective ingredients are extracted in the water extraction alcohol sedimentation and then combined with a pressure-sensitive adhesive and a percutaneous absorption enhancer in a certain proportion to be prepared into adhesive slurry containing drugs. The adhesive slurry is coated on cloth, dried, compounded with a protective layer, disinfected and equally divided into the finished product. Compared with the oral preparation, the invention has no liver and intestines first-filter action, is not influenced by degradation of gastrointestinal tract, has high biological utilization rate and no toxic effects and has evident effect on the patients with gastropathy caused by stomach heat.
Systems and methods for determining the likely responsiveness of a human cancer subject to a checkpoint blockade immunotherapy regimen are provided. Sequencing reads are obtained from samples from the subject representative of the cancer. A human leukocyte antigen type and a plurality of clones is determined from the sequencing reads. For each clone, an initial frequency Xα in the one or more samples is determined and a corresponding clone fitness score of the clone is computed, thereby computing clone fitness scores. Each such fitness score is computed by identifying neoantigens in the respective clone, computing a recognition potential for each neoantigen, and determining the corresponding clone fitness score of the respective clone as an aggregate of these recognition potentials. A total fitness, quantifying the likely responsiveness of the subject to the regimen, is computed by summing the clone fitness scores across the plurality of clones.
PURPOSE:To obtain the titled stimulation material by bonding a specific substance such as interleukin 1 to an insoluble carrier through covalent bond. CONSTITUTION:The objective lymphocyte-stimulation material for the remedy of cancer can be produced by bonding (A) one or more substances selected from the following four substances (interleukin 1, OK432, interleukin 2 produced by genetic engineering method, and gamma-interferon) to (B) an insoluble carrier (inorganic carrier such as activated carbon, glass, etc.; carrier originated from natural polymers such as cellulose, Sepharose, etc.; or synthetic polymer such as polystyrene, polyethylene, etc.) through covalent bond. Lymphocyte means hematocyte other than erythrocyte and platelet and includes the cell fraction obtained by removing granulocyte or B-cell from the lymphocyte. EFFECT:The stimulation agent is effective to stimulate and activate lymphocyte and induce a strong antitumor immune cell in high safety and operability, and is useful for the remedy, inspection, diagnosis, research, etc., of gastric cancer, pulmonary cancer, mammary cancer, etc.
The present invention relates to a traditional Chinese medicine composition for treating mycotic vaginitis, which takes more than 10 Chinese herbal medicines of radix rehmanniae glutinosae, baical skullcap root, stir-fried gardenia, grassleaf sweelflag rhizome etc. as the raw materials. The present invention has the effects of nourishing yin, clearing heat, killing parasites and stopping itch. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results with the traditional Chinese medicine. The present invention aims at providing the traditional Chinese medicine composition for treating mycotic vaginitis. The present invention is characterized by accurate efficacy, safety, reliability, no toxicity or side effects and low price.
Participants will attend dietitian clinic to have anthropometry \& dietary assessment on the same day of admission (before admission). Participants followed conventional operation procedure whereby fasting start 12am until operation. On the first day of post-operation day, participants will be reviewed by gynaecologist and dietitian. They are allowed for clear fluid once there is bowel sound. After tolerated clear fluid, they will proceed for nourishing fluid, then soft diet and they were given a regular solid diet.
PURPOSE: A food additive containing a processed panax plant extract is provided to improve and prevent bone metabolic diseases. CONSTITUTION: Health functional food for treatment and prevention of bone metabolic diseases is provided to produce with the sum of ginsenoside Rg3, Rk1, Rg5 higher than the sum of ginsenoside Rb2, Rc, Rd, and to contain a panax plant extract as an active component. Panax plants are processed ginsengs in which medicinal components are increased in a ratio of ginsenoside(Rg3+Rg5)/(Rc+Rd+Rb1+Rb2) to be 1.0 or more by treating ginseng with a high temperature ranged from 120-180 deg. C for 0.5-20 hours. The extract is water, low grade alcohol such as methanol, ethanol, butanol, etc. or a mixed solvent thereof. Food types are confectionary, bakery, ice cream, tea, fermented milk including yogurt, milk products, seasoning, alcoholic beverages, canned food, bottled food, noodles, processed dairy products, processed marine products, microorganism fermented food, bean products, grain products, processed meat products, or herbs.
1.
    Add the prescribed amount of colestipol hydrochloride granules to a glassful (three ounces or more) of water or the beverage of your choice. A heavy or pulpy juice may minimize complaints relative to consistency.
2.
    Stir the mixture until the medication is completely mixed. (Colestipol hydrochloride granules will not dissolve in the liquid.) Colestipol hydrochloride granules may also be mixed with carbonated beverages, slowly stirred in a large glass; however, this mixture may be associated with GI complaints.

Rinse the glass with a small amount of additional beverage to make sure all the medication is taken.
Hemorrhagic shock and subsequent resuscitation can cause significant dysregulation of critical systems, including the vascular endothelium. Following hemorrhage, the endothelial lining (glycocalyx) can shed, causing release of glycocalyx components, endothelial activation, and systemic inflammation. A canine model of hemorrhagic shock was used to evaluate five resuscitation fluids, including Lactated Ringers+Hetastarch, Whole Blood (WB), Fresh Frozen Plasma+packed Red Blood Cells (FFP+pRBC), and two hemoglobin-based oxygen carrier (HBOC) fluids, for their impact on glycocalyx shedding. Under anesthesia, purpose-bred adult canines were instrumented and subjected to a controlled hemorrhage with blood being drawn until a mean arterial pressure of <50 mmHg was reached or 40 % of the estimated blood volume was removed. Canines were left in shock for 45 mins before being resuscitated with one of the resuscitation fluids over 30 mins. Following resuscitation, the dogs were monitored up to 2 weeks. Following an additional 3-4 weeks for washout, the canines repeated the protocol, undergoing each resuscitation fluid individually. Blood samples were collected during each round at various timepoints for serum isolation, which was used for detection of glycocalyx biomarker. Comparison of baseline and post-hemorrhage alone showed a significant reduction in serum protein (p<0.0001), heparan sulfate (p<0.001), and syndecan-1 (p<0.0001) concentrations, and a significant increase in hyaluronan (p<0.0001) concentration. Intercomparisons of resuscitation fluids indicated minimal differences in glycocalyx markers over time. Comparisons within each fluid showed dynamic responses in glycocalyx biomarkers over time. Relative to individual baselines, syndecan-1 was significantly reduced after resuscitation in most cases (p<0.0001), excluding WB and FFP+pRBC. In all cases, VE-cadherin was significantly elevated at 24 hr compared to baseline (p<0.001). Hyaluronan was significantly elevated by 3 hr in all cases (p<0.01), except for HBOC fluids. Total glycosaminoglycans were significantly reduced only at 3 hr (p<0.001) for non-HBOC fluids. Similarly, heparan sulfate was significantly reduced with all fluids between resuscitation and 24 hr (p<0.01), except WB. The temporal changes in canine glycocalyx biomarkers were atypical of hemorrhage response in other species. This suggests that the hemorrhage lacked severity and/or typical glycocalyx biomarkers do not reflect the canine endothelium compared to other species. Further research is needed to characterize the canine endothelium and the response to resuscitation fluids.
In controlled clinical trials in adults, most patients exhibited an onset of improvement in pulmonary function within 5 minutes as determined by FEV 1. FEV 1 measurements also showed that the maximum average improvement in pulmonary function usually occurred at approximately 1 hour following inhalation of 2.5 mg of albuterol by compressor-nebulizer and remained close to peak for 2 hours. Clinically significant improvement in pulmonary function (defined as maintenance of a 15% or more increase in FEV 1 over baseline values) continued for 3 to 4 hours in most patients and in some patients continued up to 6 hours. 

Published reports of trials in asthmatic children aged 3 years or older have demonstrated significant improvement in either FEV 1 or PEFR within 2 to 20 minutes following single doses of albuterol inhalation solution. An increase of 15% or more in baseline FEV 1 has been observed in children aged 5 to 11 years up to 6 hours after treatment with doses of 0.10 mg/kg or higher of albuterol inhalation solution. Single doses of 3, 4, or 10 mg resulted in improvement in baseline PEFR that was comparable in extent and duration to a 2 mg dose, but doses above 3 mg were associated with heart rate increases of more than 10%.
Insomnia is a common complaint or disorder throughout the world. About one third of the population in the industrial countries reports difficulty initiating or maintaining sleep, resulting in a non-refreshing or non-restorative sleep. The majority of the insomniacs suffer chronically from their complaints. It has been reported that in patients with chronic insomnia lasting longer than six months, 50% had a past or current mental disorder. This raises the possibility that treatment of insomnia may reduce the risk for psychological conditions. This double-blind, placebo-controlled, parallel, randomized clinical trial is designed to assess the efficacy and safety of esmirtazapine in patients suffering from chronic primary insomnia.
PURPOSE: To map the vocal risk in professional classical singers, analyzing their self-assessment of voice and self-perception of singing voice handicap and vocal fatigue.
METHODS: The study sample comprised of 52 professional classical choir singers, aged 31 to 72 years. They answered an online questionnaire in Google Forms, addressing their characterization, self-assessment of voice, the Voice Handicap Index-10 (VHI-10), Classical Singing Handicap Index (CSHI), and Vocal Fatigue Index (VFI).
RESULTS: The mean self-assessment of voice was between "Good" and "Very good" (1.2). The mean total VHI-10 score was 1.35, which is below the cutoff. The mean total CSHI score was 10.04. The mean total VFI score was 10.83, near the cutoff value. Classical singers who use their voice to give examples to students in their classes had higher scores in VHI-10 (p = 0.013), VFI voice restriction (p = 0.011), and VFI total score (p = 0.015). Besides, classical singers who already visited a Speech-Language Pathologist for voice problems had higher scores in VFI voice restriction (p = 0.040) and VFI recovery with voice rest (p = 0.019), in addition to correlations between instrument scores.
CONCLUSION: Professional classical singers did not have voice handicaps. However, their self-perception of vocal fatigue was more present when the singing voice was used, such as giving examples with their own voice in class. Having had voice problems and visited a Speech-Language Pathologist in the past led to a greater perception of vocal recovery with rest.
A system for monitoring the health and medical requirements of a plurality of patients located at remote sites and providing these requirements to a care center. At the patient site, there is a base unit, which can be connected to a number of sensors and/or recorders with sensors. The sensors are for monitoring the patient's medical state and the recorders are for recording the medical data. The base unit stores the data and transfers the data to a care center, where the data is stored and analyzed. The care center may likewise communicate with the base unit and may reconfigure the base unit based on the data analyzed. The data retrieved from the base units is accessible on a local area network and care providers of the patients may monitor their patients by accessing the local area network.
It is intended to provide a method of stabilizing reduced coenzyme Q10 which is useful in foods with nutrient function claims, foods for specific health uses and the like; a method of preserving the same; and so on. Moreover, a process whereby reduced coenzyme Q10 with good qualities can be efficiently obtained by an industrially adequate method is provided. Reduced coenzyme Q1 0 is brought into contact with ascorbic acid or its derivative or citric acid or its derivative to thereby give a stabilized composition in which the reduced coenzyme Q10 can be handled as being protected from oxidation by molecular oxygen and which can be stored stably. Further, reduced coenzyme Q10 is crystallized in the presence of ascorbic acid or its derivative, etc. Thus, it can be converted into crystals while minimizing the formation of oxidized coenzyme Q10 as a by-product, thereby giving reduced coenzyme Q10 with good qualities. Moreover, oxidized coenzyme Q10 is converted into reduced coenzym e Q10 by reducing with the use of ascorbic acid or its derivative and the thus formed reduced coenzyme Q10 is subsequently crystallized in the presence of the ascorbic acid or its derivative so that reduced coenzyme Q10 with good qualities can be produced by a simplified procedure within a shorter period.
A total of 70 participants were randomized to each group for 35 people, the control group receiving the oral patient education and the experimental group receiving patient education using mobile applications. Both groups collected data using "Wound Care Knowledge Scale," "Wound Care Skills Scale," "State Trait Anxiety Inventory" and "Heart Rate Variability" at three phases, including before the intervention (T1), after 3 times of intervention (T2), and before discharge from hospital (T3).
Apple polyphenols (APs) have gained attention for their various bioactivities, while no studies on anti-liver fibrosis activity are reported. This study evaluated the protective effect of APs on liver fibrosis using LPS-treated activated HSC-T6 cells and alcohol-treated liver fibrosis (ALF) mice. The results indicated that APs inhibited HSC-T6 cells activation in vitro and reduced the level of serum hyaluronic acid (HA) (p < 0.05), decreased fibrogenesis marker expression (p < 0.05), thereby alleviating ALF. In addition, APs (800 mg/kg b.w.) decreased the Firmicutes/Bacteroidetes ratio (p < 0.05) in ALF mice, inhibited LPS accumulation in the liver tissue and serum (p < 0.05), and significantly inhibited the TLR4/NF-κB/TGF-β signaling in mice liver. In conclusion, APs markedly ameliorated ALF, possibly by improving gut microbiota homeostasis, decreasing the translocation of bacterial endotoxins to the blood, and suppressing the TLR4/NF-κB/TGF-β signaling pathway, indicating its potential as lead compounds for functional foods and/or drugs against ALF.
BACKGROUND: Antibiotic resistance is one of the main concerns of public health, and the whole world is trying to overcome such a challenge by finding novel therapeutic modalities and approaches. This study has applied the sequence hybridization approach to the original sequence of two cathelicidin natural parent peptides (BMAP-28 and LL-37) to design a novel HLM peptide with broad antimicrobial activity.
METHODS: The physicochemical characteristics of the newly designed peptide were determined. As well, the new peptide's antimicrobial activity (Minimum Inhibitory Concentration (MIC), Minimum Bacterial Eradication Concentration (MBEC), and antibiofilm activity) was tested on two control (Staphylococcus aureus ATCC 29213, Escherichia coli ATCC 25922) and two resistant (Methicillin-resistant Staphylococcus aureus (MRSA) ATCC BAA41, New Delhi metallo-beta- lactamase-1 Escherichia coli ATCC BAA-2452) bacterial strains. Furthermore, synergistic studies have been applied to HLM-hybridized peptides with five conventional antibiotics by checkerboard assays. Also, the toxicity of HLM-hybridized peptide was studied on Vero cell lines to obtain the IC50 value. Besides the percentage of hemolysis action, the peptide was tested in freshly heparinized blood.
RESULTS: The MIC values for the HLM peptide were obtained as 20, 10, 20, and 20 μM, respectively. Also, the results showed no hemolysis action, with low to slightly moderate toxicity action against mammalian cells, with an IC50 value of 10.06. The Biomatik corporate labs, where HLM was manufactured, determined the stability results of the product by Mass Spectrophotometry (MS) and High-performance Liquid Chromatography (HPLC) methods. The HLM-hybridized peptide exhibited a range of synergistic to additive antimicrobial activities upon combination with five commercially available different antibiotics. It has demonstrated the biofilm-killing effects in the same concentration required to eradicate the control strains.
CONCLUSION: The results indicated that HLM-hybridized peptide displayed a broad-spectrum activity toward different bacterial strains in planktonic and biofilm forms. It showed synergistic or additive antimicrobial activity upon combining with commercially available different antibiotics.
Pramipexole dihydrochloride tablets contain pramipexole dihydrochloride a nonergot dopamine agonist. The chemical name of pramipexole dihydrochloride is (S)-2-amino-4,5,6,7-tetrahydro-6(propylamino)benzothiazole dihydrochloride monohydrate. Its empirical formula is C10H17N3S•2HCl•H2O, and its molecular weight is 302.27. The structural formula is: 

  


  


Pramipexole dihydrochloride is a white to almost white crystalline powder. Melting occurs in the range of 296˚C to 301˚C, with decomposition. Pramipexole Dihydrochloride is freely soluble in water, soluble in methanol, sparingly soluble to slightly soluble in ethanol (96%) and practically insoluble in methylene chloride.  
Pramipexole dihydrochloride tablets, for oral administration, contain 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, or 1.5 mg of pramipexole dihydrochloride, USP. Inactive ingredients consist of mannitol, corn starch, colloidal silicon dioxide, povidone, and magnesium stearate.
Autoimmune pancreatitis (AIP) is classified into type 1 (IgG4-related) and type 2 (IgG4-unrelated) and the interpretation of pancreatic biopsy findings plays a crucial role in their diagnosis. Needle biopsy of type 1 AIP in the acute or subacute phase shows a diffuse lymphoplasmacytic infiltrate, storiform fibrosis, obliterative phlebitis, and the infiltration of many IgG4-positive plasma cells. In a later phase, changes become less inflammatory and more fibrotic, making interpretations more challenging. Confirmation of the lack of 'negative' findings that are unlikely to occur in type 1 AIP (e.g., neutrophilic infiltration, abscess) is important to avoid an overdiagnosis. The number of IgG4-positive plasma cells increases to >10 cells/high-power field (hpf), and the IgG4/IgG-positive plasma cell ratio exceeds 40 %. However, these are minimal criteria and typical cases show >30 positive cells/hpf and a ratio >70 % even in biopsy specimens. Therefore, cases with a borderline increase in this number or ratio need to be diagnosed with caution. In cases of ductal adenocarcinoma, the upstream pancreas rarely shows type 1 AIP-like changes; however, the ratio of IgG4/IgG-positive plasma cells is typically <40 %. Although the identification of a granulocytic epithelial lesion (GEL) is crucial for type 2 AIP, this finding needs to be interpreted in conjunction with a background dense lymphoplasmacytic infiltrate. An isolated neutrophilic duct injury can occur in peritumoral or obstructive pancreatitis. Drug-induced pancreatitis in patients with inflammatory bowel disease often mimics type 2 AIP clinically and pathologically. IL-8 and PD-L1 are potential ancillary immunohistochemical markers for type 2 AIP, requiring validation studies.